Kaempferol ameliorates BMSCs senescence in postmenopausal osteoporosis by targeting Sp1 to activate FUNDC1-mediated mitophagy.

Linghanqing Wang, Yangyang Qu, Zhehan Hu, Puzhou Lei, Xurong Tian, Xinyue Yang, Sida Chen, Cheng Li, Binbin Wei, Lei Li

Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.Department of Orthopaedic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China. · pubmed

Paper

Abstract

Postmenopausal osteoporosis (PMOP) is the predominant form of primary osteoporosis. Its etiology remains incompletely elucidated, and the senescence of bone marrow mesenchymal stem cells (BMSCs) is potentially a contributing factor. Kaempferol (Ka), a common flavonoid with antioxidant and anti-inflammatory effects, is a prospective candidate for therapeutic intervention in osteoporosis. However, its impact on BMSC senescence and the underlying mechanisms remains to be elucidated.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Kaempferol ameliorates BMSCs senescence in postmenopausal osteoporosis by targeting Sp1 to activate FUNDC1-mediated mitophagy. The paper is relevant as it explores the mechanisms underlying cellular senescence, which is a key aspect of aging and age-related diseases.

Author of this paper? Send a correction.